Objectives: Use of Biologics to treat and prevent recurrence of scarring alopecia and alopecia areata. Identify the anti inflammatory properties in adipose stem cells, PRP, and bone marrow. Avoid costly, marginally effective, and risky medications such as prolonged steroid use and JAK inhibitors

Objectives: This presentation explores exosome therapy for scarring alopecia, a condition marked by irreversible follicular destruction due to fibrosis, trauma, or inflammation. A brief review of a 300-subject study on exosome therapy for androgenic alopecia establishes its role in follicular regeneration and scalp homeostasis. We then examine case studies using the same protocol, assessing whether exosome-driven signaling, immunomodulation, and extracellular matrix remodeling can promote follicular neogenesis in cicatricial alopecia, defining the therapeutic limits of exosome-based interventions.

Objectives: To provide a comprehensive management approach for AA patients receiving JAK inhibitors, focusing on patient selection, monitoring, adverse effect management, and long-term care.

Introduction: Jak inhibitors have revolutionized the treatment landscape for alopecia areata (AA), offering significant hair regrowth in many patients. However, optimizing patient management during JAK inhibitor therapy is crucial to maximize efficacy while minimizing risks.

Materials / method: This review synthesizes current guidelines, clinical trial data, and expert consensus on JAK inhibitor use in AA. It emphasizes patient evaluation, treatment initiation, monitoring protocols, and strategies for addressing side effects

Results: Real candidates for JAK inhibitor therapy are patients with moderate-to-severe AA who have not responded to conventional treatments. Prior to initiation, patients should undergo thorough screening for infections, malignancies, and other contraindications. Regular monitoring includes complete blood counts, liver function tests, and lipid profiles every 4–8 weeks. Adverse effects such as infections, lipid abnormalities, and rare hematologic events require prompt management, including dose adjustments or temporary treatment cessation. Long-term management involves assessing sustained response.

Conclusion: JAK inhibitors represent a significant advancement in AA treatment, but require careful patient selection, vigilant monitoring, and proactive management of adverse effects. Adherence to structured protocols ensures optimal outcomes and safety for AA patients undergoing JAK inhibitor therapy.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。